Obesity and type 2 diabetes mellitus are the major noncommunicable public health problem of the 21st century. The best strategy to tackle this problem is to develop strategies to prevent/treat obesity. However, it is becoming clear that despite successful research identifying weight regulatory pathways, the development of the obesity epidemic is outpacing scientific progress. The lack of success controlling the obesity epidemic in an aging population will result in another subsequent uncontrolled epidemic of complications. Our research focuses on the mechanisms causing lipotoxicity aiming to identify suitable strategies to prevent or at least retard the development of the metabolic syndrome. Previous work using transgenic and knockout mouse models has shown an interplay between white adipose tissue and skeletal muscle linking fatty acid (FA) synthesis with reciprocal effects on FA oxidation. Work from our lab and others suggests that defective adipose tissue is a key link between obesity, insulin resistance and type 2 diabetes mellitus by promoting the development of lipotoxicity in peripheral tissues. We propose a series of models to describe the process by which the adipose tissue could react to an energy-rich environment and responds depending on genetic and physiological factors, impacting on the functions of other peripheral tissues. We suggest that by examining hypotheses that encompass multiple organs and the partitioning of energy between these organs, a suitable strategy can be devised for the treatment of chronic obesity.
Introduction
Obesity and its associated disorders is one of the most pressing health issues facing medicine today. Much time and effort has been spent in order to identify the basic molecular and physiological biology concerning the development of obesity in an attempt to identify suitable targets for pharmacological intervention. Although the main goal is understanding how obesity occurs to try to prevent its development, it is very clear that the present epidemic requires quick action. Our approach to understanding obesity is to formulate how obesity is linked to diabetes and cardiovascular disease, in an attempt to prevent the deleterious effects of obesity and improve quality of life. In our opinion, lipotoxicity is a major, if not the central, factor linking obesity and cardiovascular outcomes. Here, we present our hypotheses related to the development of lipotoxicity and some of the approaches that our lab has taken to further the understanding how certain molecules involved in lipogenesis de novo contribute to lipotoxicity.
From a thermodynamic perspective, the regulation of body adipose tissue can be described as a linear equation (Figure 1 ), balancing both food intake and energy expenditure to derive the amount of fat stored. Thus, increases in food intake or decreases in energy expenditure result in elevated fat deposition. An additional component of the equation in the form of 'energy partitioning' can influence the levels of each factor in the equation. For instance, fat may be directed to either oxidative processes in skeletal muscle or brown adipose tissue, or to triglyceride (TG) storage in white adipose tissue (WAT). There is also recent evidence for a role in energy partitioning in being able to control the levels of food intake. While it is unclear as to whether a specific alteration in energy partitioning is vital for the initial development of most forms of obesity, identification of factors involved in the regulation of energy partitioning could be candidates for drugs for the treatment of obesity and its complications.
Energy homeostasis is a complex, integrated system designed to prevent negative energy balance, as illustrated by the decrease in energy expenditure during fasting. Thus, for the treatment of obesity where a negative energy balance is required, this simple strategy has proved not to be effective. The networks controlling energy homeostasis show both compensatory feedback and redundancy. Thus, it is likely that multiple steps should be targeted simultaneously to achieve a suitable reduction in body weight. We speculate that by alteration of two factors of the energy balance equation, reductions in energy acquisition, combined with increases in energy dissipation, via preferential partitioning of energy to oxidative tissues should produce long-term reductions in the amount of fat storage.
In our opinion, WAT is a key organ for the development of the metabolic syndrome. It is well known that insulin resistance (in obesity) or insulin insufficiency (in diabetics) results in two specific effects on WAT: (1) insulin-stimulated uptake of glucose and fatty acids (FAs) into the WAT is reduced 1 and (2) there is impaired suppression of FA and glycerol release postprandially. 2, 3 This increases net FA flux towards tissues such as the skeletal muscle, heart, liver and the pancreatic b-cell, which unchecked may result in eventual lipotoxicity. Thus, lipotoxicity may be prevented by either an increased WAT FA storage capacity or by increased FA oxidation capacity in other tissues. FA oxidation and lipogenesis are highly integrated processes. For example, it has been previously shown in genetically modified mouse models with inhibition of FA storage in WAT there is upregulation of FA oxidation in skeletal muscle, demonstrating the interplay of energy fluxes between the two organs. One such model is the diacylglycerol acyltransferase (DGAT) knockout mice (DGAT is the enzyme that catalyses the final acylation step of triacylglyceride synthesis 4 ). This shows reduced fat deposition and resistance to diet-induced obesity, due to the disruption in FA storage. In addition, DGAT knockout mice show elevated energy expenditure and increased activity, suggesting an increase in FA oxidation. 5 Similarly, deletion of acetyl-CoA carboxylase 2 (ACC2), a key enzyme for de novo FA synthesis, leads to a lean mouse showing an increase in FA oxidation. 6 This is due to a fall in malonyl-CoA, the product of the ACC reaction. Malonyl-CoA is a potent inhibitor of carnitinepalmitoyl transferase 1 (CPT1), which transports FA moieties into the mitochondria for b-oxidation. 7 Thus, the absence of ACC2 reduces the cellular concentration of malonyl-CoA, removes the inhibition of CPT1 and allows FA oxidation to be maintained. A further model, the skeletal muscle-specific uncoupling protein 3 (UCP3) transgenic mouse also has increased FA oxidation, due to increased mitochondrial uncoupling. 8 An interesting observation is that these mice remain lean despite hyperphagia, suggesting that elevations in FA oxidation capacity are powerful enough to overcome secondary effects on food intake.
Lipotoxicity and interorgan communication
Whereas the interplay between de novo lipogenesis and FA oxidation may be key for lipotoxicity in a specific tissue, the understanding of this interplay becomes more complex when we consider its global impact in an in vivo model. According to the experience gained with several animal models, we can establish a number of different scenarios featuring excess energy and/or nutrition availability ( Figure 2 ). In a normal physiological scenario, energy intake is primarily partitioned towards homeostatic energy expenditure with excess energy being stored in WAT in the form of TGs and in the liver and skeletal muscle in the form of carbohydrates. Interruptions in this pattern of energy flow may lead to compensatory responses in other tissues that may be unsuitable for that particular tissue to carry out chronically. In the first pathological scenario, we suggest that when there is an impairment of fat deposition in WAT despite the presence of elevated energy intake, there is an increase in serum free FAs (FFA) and accumulation of FAs in tissues such as the liver, skeletal muscle and the pancreas. Insufficient attempts by these tissues to dispose of the FAs by elevation of FA oxidation leads to chronic FA deposition and lipotoxicity, followed by insulin resistance, fatty liver and insulin secretion failure. Such a scenario can occur in lipodystrophic disorders, where the WAT is unable to expand sufficiently to store delivered FAs. 9 In the second scenario, increased energy availability results in the hypertrophic expansion of the WAT. Evidence suggests that hypertrophic adipocytes are more insulin resistant 1, 3 and display alterations in the repertoire of adipokines that enhance the progression of insulin resistance. 10 In the hypertrophic scenario, adipocytes may be unable to store all of the delivered FAs and incompletely suppress hormone-sensitive lipase-mediated FA output due to insulin resistance. This results in a reduced capability for FA storage and retention (depending on the severity of the insulin resistance), leading to elevated circulating FFAs, together with compensatory increases in oxidation in other peripheral tissues to dispose of excess FAs. Again, chronic exposure of peripheral tissues to this insult may
Food intake -Energy expenditure = Fat
Partitioning of energy Figure 1 The fat derivation equation. The amount of fat stored in an organism is a balance between the amount of energy absorbed and energy expenditure of the organism. In addition, how the energy is partitioned may influence food intake (eg by increasing WAT content and serum leptin levels). By externally influencing one, some or all of these components, the amount of fat deposition may be reduced.
facilitate the development of the metabolic syndrome. In the third scenario, instead of the development of hypertrophic, insulin-resistant adipocytes, excess energy input results in the formation of hyperplastic adipocytes. These have the metabolic advantage of retaining insulin sensitivity and a favourable pattern of signalling molecule secretion. Thus, the expansion of the WAT is via smaller but more numerous adipocytes, able to facilitate the deposition of FAs protects other tissues from lipotoxicity by sequestering the FAs away from these tissues. The result of this pattern of adipocyte expansion is obesity, but without the associated metabolic syndrome or defects in the insulin sensitivity of peripheral tissues. An example of this scenario may be treatment with thiazolidinediones, which have been shown at least in rodent models to promote preadipocyte recruitment favouring hyperplasic remodulation of the adipose tissue.
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The final two scenarios examine the effect of increasing skeletal muscle FA oxidation. The fourth scenario shows the result derived from a muscle increase in FA oxidative Mechanisms causing lipotoxicity C Lelliott and AJ Vidal-Puig capacity perhaps by genetic or pharmacological intervention. An example of this model could be the mouse transgenic for UCP3 overexpression in skeletal muscle. 8 In this case, the driving force is increased FA oxidation that could act as an energy sink, diverting FAs away from storage tissues such as WAT (resulting in a lean phenotype), and also away from other tissues less capable of handling FAs adequately (eg liver and beta cell). In this respect, normal insulin sensitivity is maintained. In the fifth scenario, we present a model for obesity intervention suggesting that strategies directed to, on one hand, prevent fat deposition combined with an increase in FA oxidation in skeletal muscle may facilitate safe weight loss. In this case, skeletal muscle will act as an avid FA sink, preventing evolution of lipotoxicity in the pancreas and liver.
Experimental paradigms to study lipotoxicity
Our laboratory is currently exploring some of these experimental paradigms. Firstly, we are looking at questions concerning the functioning of the WAT, considering mechanisms of adipogenesis and remodelling the constitution of the WAT in terms of size and function of the adipocyte as a strategy to increase the storage capacity of the adipose tissue and prevent lipotoxicity. Secondly, we are exploring the nature of interorgan communication both in normal situations and lipotoxicity. This involves examining the roles of molecules secreted by the WAT, including FAs and adipokines, signalling molecules secreted by the adipocyte. We are interested in the mechanisms required for the development of lipotoxicity and more specifically whether the machinery of de novo lipogenesis is important. In addition, we are exploring the potential of FA oxidation as a mechanism to prevent or reverse the course of lipotoxicity.
One of the key questions surrounding the mechanism of lipotoxicity is whether accumulation of TGs is the cause of lipotoxicity, or simply a marker for other mechanisms. Once FAs such as palmitate enter nonadipose tissues, they are directed towards FA oxidation, stored as TGs or alternatively directed towards the formation of deleterious reactive species. It is not known whether the presence of TGs themselves or their FA derivatives that elevate the levels of toxic molecules such as ceramides and reactive oxygen species. 12 Both of these molecules are potentially apoptotic, via the activation of caspases. WAT can directly influence the amount of TGs accumulated in tissues such as skeletal muscle by the secretion of two groups of compounds: (a) adipokines such as leptin, adiponectin and TNFa are secreted by the WAT and have been shown to affect insulin sensitivity and fuel oxidation. [13] [14] [15] (b) FAs, either from stored TGs or from de novo synthesis in the WAT, are known to have signalling properties that can affect insulin sensitivity and contribute directly to lipotoxicity. 16 A key transcription factor for regulating FA metabolism, sterol regulatory element-binding protein 1 (SREBP1), may be a key molecule for the development of lipotoxicity.
SREBP1c, a gatekeeper for lipotoxicity
Mammalian cells tightly control levels of cholesterol and FA in their membranes in order to maintain form, fluidity and function. The mechanism of this control is via a feedback regulatory system that regulates gene transcription of enzymes involved in FA and cholesterol biosynthesis. SREBP1 is a member of the basic helix-loop-helix (bHLH) family of transcription factors. 17, 18 The SREBPs are tripartite proteins consisting of: (a) an N-terminal domain of approximately 480 amino acids that is a transcriptional activator of the bHLH-leucine zipper family; (b) a hairpin membrane anchor domain of around 80 amino acids comprising two transmembrane segments separated by a 31-amino-acid hydrophilic loop; and (c) a C-terminal domain of around 590 amino acids that plays a regulatory role. 19 The dualbinding specificity of SREBP1c to E-boxes and SREs is due to a critical tyrosine residue in the DNA-binding region, which replaces the canonical arginine found in typical E-box binding factors. 20 SREBP1 occurs in two isoforms, SREBP1a and 1c, which are differentially spliced at 5 0 -and 3 0 -end.
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SREBP1c exhibits lower transcriptional activity than SREBP1a, presumably due to its shorter 5 0 -end. 22 Expression of SREBP1a and SREBP1c is also tissue specific. It has been shown that SREBP1c is highly expressed in the WAT, liver, adrenal gland and brain, with appreciable expression in muscle. 21, 23 SREBP1a expression is seen mostly in cell lines and the spleen. 21 A second family member, SREBP2, is transcribed from a separate gene to SREBP1 24 and is thought to primarily activate transcription of genes involved in cholesterol biosynthesis, whereas SREBP1 activates genes involved in FA synthesis. 25 Members of the SREBP family are initially transcribed as an immature precursor that is embedded in the endoplasmic reticulum (ER). Upon synthesis, SREBP proteins bind to SREBP-cleavage activating protein (SCAP). 26 This molecule is a sensor for cholesterol levels within the cell or membrane. When the cell is cholesterol depleted, SCAP transports the SREBP to the Golgi stack. 27 Here, the SREBP molecule is cleaved by the site-1 protease, removing a portion of the Cterminus, but leaving the N-terminus in the membrane. The SREBP then returns to the ER where it is subsequently cleaved by the site-2 protease. This releases the N-terminal region containing the DNA-binding region and activation domain into the cytoplasm, and the now mature SREBP transfers to the nucleus where it activates transcription.
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When cells are overloaded with sterols, the conformation of SCAP is altered 28 and blocks the interaction of SCAP with the vesicle protein COPII. 29 Thus, the SCAP/SREBP complex fails to leave the ER, meaning that mature SREBP is not formed and SREBP-mediated transcription does not occur. Interestingly, this cholesterol-regulated mechanism seems to also
Mechanisms causing lipotoxicity C Lelliott and AJ Vidal-Puig affect FA synthesis level, 30 suggesting a link between the control of cholesterol and FA metabolism. More recently, the INSIGs (insulin-stimulated genes) have been shown to be proteins that inhibit SREBP cleavage by inhibiting the migration of the SREBP-SCAP complex from the ER to the Golgi. 31, 32 SREBP1c has been identified as the nutritionally regulated form of SREBP1. This isoform regulates the expression of many of the genes involved in de novo FA and TG synthesis. 22 This includes the major genes encoding the primary enzymes of de novo FA synthesis, ACC and FAS. Many groups have established that insulin upregulates SREBP1c mRNA and mature SREBP1 protein and is accompanied by increases in FA biosynthetic gene expression. [33] [34] [35] As the product of the ACC-catalysed reaction, there is also an increase in the levels of malonyl-CoA, leading to the inhibition of CPT1 and mitochondrial FA oxidation (Figure 3 ). Work in our lab has shown that in human WAT, the majority of SREBP1 expressed is in the SREBP1c isoform. 35 In addition, SREBP1c expression is higher in human mature adipocytes than in both undifferentiated and differentiated primary adipocytes. This suggests that mature adipocytes are the component of the WAT in which SREBP1c is likely to have its greatest effects. We have also been able to show that SREBP1 mRNA and protein expression in WAT and at mRNA level in skeletal muscle is increased by insulin. 35 This suggested that SREBP1 is regulated in both of these insulin sensitive tissues. It is not surprising in this respect that in lean vs morbidly obese humans, SREBP1 gene expression is decreased in adipose tissue of the morbidly obese group. However, in skeletal muscle, obesity has no effect on the levels of SREBP1 and only skeletal muscle from diabetics show a decrease in SREBP1, an effect that can be reversed with insulin to normal stimulated levels. The decrease in SREBP1 mRNA can be reproduced in human primary adipocyte cultures using TNFa. 35 PGC1a. 39 Deiodinase II produces T3, the ligand for the thyroid hormone receptor (TR). PGC1a has effects via coactivation of the UCP1 enhancer element with both PPAR and TR, thus stimulating UCP1 production. 40 In addition, PGC1a coactivates genes involved in mitochondrial biogenesis via nuclear respiratory factor-1. 41 Insulin elevates SREBP1 mRNA and mature SREBP1 levels, which in turn increases expression of FA biosynthetic gene expression. The product of the reaction catalysed by ACC, malonyl-CoA, is a powerful inhibitor of the mitochondrial FA importer CPT-1, blocking FA oxidation. Thus, control of FA synthesis and oxidation can be integrated through a single mechanism.
overexpression have been seen in both white adipocytes and skeletal muscle. Unilocular white adipocytes adopt a multilocular morphology, with increased UCP1 expression and mitochondrial biogenesis reminiscent of brown adipocytes. 42 In skeletal muscle, PGC1a overexpression yields increased UCP2 expression, increased mitochondrial biogenesis, increased oxygen consumption and a switch to a red fibre type in transgenic animals. 43 Thus, factors relating to PGC1a may be ideal candidates for the elevation of energy expenditure. Both our group and Bruce Spiegelman's group isolated the gene encoding PGC1b, a new homologue of PGC1a. 44, 45 Data from our lab have shown that PGC1b is highly expressed in tissues with a high mitochondrial content such as skeletal muscle and the heart, supporting a role in mitochondrial function. However, unlike PGC1a, PGC1b is unaffected in rat liver by food withdrawal or cold exposure, suggesting that PGC1b may play a role in basal mitochondrial function. 45 To support this, it has been found that ectopic expression of PGB1b is able to both induce mitochondrial biogenesis and increase mitochondrial oxygen consumption in muscle cell lines to levels equivalent to that seen in PGC1a-overexpressing cells. 45, 46 Further work is needed to establish the exact biological role that PGC1b plays in specific tissues and to look at potential mechanisms of the regulation of PGC1b that may be used in future therapies. In addition, it is interesting to note that the heart has high levels of PGC1b, a fact which is likely to be related to the heart's preference for FAs as a fuel source. Tissuespecific deletions of PGC1b may be required to further source the particular function of PGC1b in each tissue. In summary, we consider that a purely antiobesity strategy has a narrow therapeutic margin, since reduction of adipose tissue mass is likely to result in the unwanted deposition of FAs to tissues such as the liver, skeletal muscle and the pancreas, which may have a limited capacity to safely store and dispose of FAs. A more advantageous approach would be to combine a treatment regime including mechanisms for both decreasing fat deposition in the WAT and increasing fat oxidation in skeletal muscle and other tissues.
